Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction
Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction
Aerovate Therapeutics將探討包括但不限於收購、合併、反向合併、業務組合、清算或其他交易的戰略替代方案。
Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
Aerovate Therapeutics, Inc.（納斯達克：AVTE）先前宣佈暫停招募和關閉吸入式iMatinib肺動脈高壓臨床試驗（IMPAHCT）的第三階段和長期延伸研究，今天宣佈將開展全面檢查戰略選擇以最大化股東價值。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間